NT5E (IPH5301 Biosimilar) Recombinant Monoclonal Antibody
-
貨號:CSB-RA723415MB7HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:NT5E(IPH5301 Biosimilar Antibody)重組單克隆抗體是一款專為科研用途開發(fā)的生物制劑,主要針對NT5E靶點(diǎn)設(shè)計。NT5E作為一種細(xì)胞表面酶,在核苷酸代謝及免疫調(diào)節(jié)中發(fā)揮重要作用,其異常表達(dá)與多種疾病的發(fā)生發(fā)展密切相關(guān)。該重組單克隆抗體通過基因工程技術(shù)制備,具有高特異性和親和力,能夠精準(zhǔn)識別并結(jié)合NT5E蛋白,為相關(guān)機(jī)制研究提供可靠工具。 本產(chǎn)品采用重組表達(dá)系統(tǒng)生產(chǎn),經(jīng)嚴(yán)格的質(zhì)量控制確保批次間一致性和高純度。其核心優(yōu)勢在于可特異性阻斷NT5E的酶活性或信號傳導(dǎo)通路,適用于細(xì)胞模型、動物模型等多種實(shí)驗(yàn)場景,助力研究人員深入探索NT5E在腫瘤微環(huán)境、免疫抑制、代謝性疾病等領(lǐng)域的功能機(jī)制。 在科研應(yīng)用中,該抗體可用于等檢測手段,也可通過體外中和實(shí)驗(yàn)或體內(nèi)干預(yù)實(shí)驗(yàn),分析NT5E對細(xì)胞增殖、分化及相關(guān)信號通路的影響。其嚴(yán)謹(jǐn)?shù)脑O(shè)計和可靠的性能,為揭示NT5E的生物學(xué)功能及潛在臨床價值提供了有力支持。 作為科研用試劑,本產(chǎn)品僅供實(shí)驗(yàn)室研究使用,不用于臨床診斷或治療。其開發(fā)旨在推動NT5E相關(guān)基礎(chǔ)研究的進(jìn)展,為疾病機(jī)制解析和新藥研發(fā)提供關(guān)鍵實(shí)驗(yàn)材料。
-
Uniprot No.:
-
基因名:
-
別名:IPH-5301 research-grade biosimilar ;NT5E antibody; NT5 antibody; NTE antibody; 5'-nucleotidase antibody; 5'-NT antibody; EC 3.1.3.35 antibody; EC 3.1.3.5 antibody; EC 3.1.3.89 antibody; EC 3.1.3.91 antibody; EC 3.1.3.99 antibody; 5'-deoxynucleotidase antibody; Ecto-5'-nucleotidase antibody; IMP-specific 5'-nucleotidase antibody; Thymidylate 5'-phosphatase antibody; CD antigen CD73 antibody
-
反應(yīng)種屬:Human
-
免疫原:Recombinant Human NT5E protein
-
免疫原種屬:Homo sapiens (Human)
-
標(biāo)記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應(yīng)用說明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:3-4 weeks
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能:Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.
-
基因功能參考文獻(xiàn):
- Changes in the local expression and activity of CD39 and CD73 in calcified valves suggest their potential role in calcific aortic valve disease. PMID: 30056298
- High expression of NT5E is associated with Prostate Cancer. PMID: 29916747
- Case Report: identify novel mutations in the NT5E gene in patient with calcification of joints and arteries. PMID: 28825389
- High CD73 expression is associated with breast cancer. PMID: 29047106
- High CD73 expression is associated with neoplasms. PMID: 29514610
- NT5E-targeting miRNAs (miR-30b and miR-340) function as tumor suppressors PMID: 29155108
- soluble CD73 might be used as serologic prognostic biomarker in patients with metastatic melanoma patients. PMID: 29202855
- High CD73 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity. PMID: 29367423
- analysis of how inhibitors block human CD73 and block efficiently its enzymatic function in the low micromolar range through a non-competitive inhibition mechanism PMID: 29377887
- The Ecto-5'nucleotidase, together with alkaline phosphatase, also expressed apically in oviductal epithelium, complete the hydrolysis sequence by dephosphorylating AMP to adenosine. PMID: 29273916
- this paper shows that simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro PMID: 28389406
- high levels of CD73 are significantly associated with reduced overall survival in patients with head and neck squamous cell carcinoma PMID: 27557512
- Studied role of miR-30a in colorectal cancer(CRC). Found miR-30a is downregulated in CRC, and it inhibits cell proliferation in CRC by reducing expression of CD73. PMID: 28464916
- we demonstrated the existence of CSCs in both cultured ccRCC cell line and tissues, and CD73 as a cell-surface biomarker for ccRCC CSC-like cells. PMID: 28404888
- Induction of ecto-5'-nucleotidase/CD73 by radiation contributes to the radiosensitivity of T24 urinary bladder cancer cell line. PMID: 29305710
- Report prognostic impact of CD73 expression in non-small lung cancers. PMID: 28060732
- Data show that MiR-422a and its target CD73 are involved in early loco(regional) recurrence of head and neck squamous cell carcinoma (HNSCC) tumors and are targets for personalized medicine. PMID: 27281619
- HPV+ cervical cancer cells express higher levels of CD73 than HPV- cells, and this expression is associated with the production of larger amounts of adenosine, as well as a stronger inhibition of proliferation, activation, and cytotoxic activity of CD8+ T cells via interaction with A2A adenosine receptor PMID: 28950987
- High CD73 expression is associated with Melanoma Metastasis. PMID: 28652244
- Hippocampal astrogliosis observed in medial temporal lobe epilepsy patients was accompanied by a proportionate increase in A2A receptor and ecto-5'-nucleotidase/CD73 immunoreactivities. PMID: 27650530
- High CD73 expression is associated with cervical cancer. PMID: 28202050
- Endogenous Plastic Somatic (ePS) cells in a latent state, i.e. lacking SOX2, OCT3/4 and NANOG (SON) expression, in non-diseased breast specimens through immunohistochemical analysis of previously identified ePS-specific biomarkers (CD73(+), EpCAM(+) and CD90(-)). PMID: 27705752
- Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression. PMID: 28193736
- CD73 polymorphisms play a role in calciphylaxis development in dialysis patients. PMID: 28212442
- CD73 expression is upregulated in NSCLC and is correlated with a decrease in miR-30a-5p expression. PMID: 28158983
- This study found that in septic critically ill patients the soluble CD73 levels were generally low and showed a further decrease from 0h to 24h. Moreover, the sCD73 levels were higher in acute kidney injury (AKI) versus non-AKI patients and in non-survivors with severe sepsis than in survivors, but were not independently associated either with the development of AKI or 90-day mortal PMID: 27732656
- concluded that CD39 and CD73 are molecular targets for the development of drugs for ALF patients care PMID: 27899277
- Genetic polymorphism of NT5E may contribute to the pathogenesis of calcific aortic valve disease. PMID: 27906615
- Oxidized low density lipoproteins modulate CD39 and CD73 activity in the endothelium. PMID: 27906627
- CD73 may play an important role in breast cancer stem cells. PMID: 27670764
- This study aimed to investigate the activities of purinergic system ecto-enzymes present on the platelet surface as well as CD39 and CD73 expressions on platelets of sickle cell anemia treated patients. PMID: 27044834
- Aim of the present study was to investigate the role of CD73 in glioma blood vessels; results found that the expression of CD73 in glioma vascular cells is significantly decreased, and this reduction may down-regulate the expression of brain microvascular endothelial tight junction-related proteins PMID: 26884147
- These results provide a finely mapped epitope that can be targeted for selective, potent, and non-competitive inhibition of CD73, as well as establish a strategy for inhibiting enzymes that function in both membrane-bound and soluble states. PMID: 26854859
- CD73 promotes the growth of human colorectal cancer cells through EGFR and the b-catenin/cyclin D1 signaling pathway. CD73 may be used as a valuable biomarker of colorectal cancer. PMID: 26708311
- Our study revealed that CD73 is an independent prognostic factor in prostate cancer. PMID: 26253870
- The NT5E gene is involved in both intrinsic and acquired resistance to platinum-based drugs in ovarian cancer. [meta-analysis] PMID: 26629888
- CD73 expression was significantly correlated with the invasion into adjacent organs. PMID: 26691441
- report on a Chinese family with CALJA and novel compound heterozygous mutations (c.1360G>A (p.Gly454Arg) and c.1387C>T (p.Arg463X)) in NT5E PMID: 26178434
- findings reveal that CD73-generated adenosine promotes epithelial integrity and suggest why loss of CD73 in endometrial cancer allows for tumor progression PMID: 26642367
- CD73 activity from any host cell type is not required for the monocyte/macrophage polarization in the peritoneum towards a pro- or an anti-inflammatory phenotype in vivo PMID: 26258883
- these data suggest a possible role for CD73 and A2A in inflammation observed in patients with T2D and obesity mediated via apoptosis. PMID: 25770019
- This study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in high-grade serous ovarian cancers. PMID: 26363007
- role of CD73 and CD39 ectonucleotidases in T cell differentiation PMID: 26226423
- Expression of NPP1 and 5'-nucleotidase by valve interstitial cells promotes the mineralization of the aortic valve through A2aR and a cAMP/PKA/CREB pathway. PMID: 25644539
- Although upregulated CD73 expression in tumor cells correlates with a poor prognosis in patients with rectal adenocarcinoma, the combination of CD73 expression in malignant epithelial cells and tumor stroma may have a better prognostic value PMID: 25677906
- rs9444348 heterozygosity is associated with increased risk of post-traumatic epilepsy development after brain injury. PMID: 26040919
- Species-specific CD73 regulation, with potential significance to cancer, fibrosis, and other diseases characterized by changes in CD73 expression and function. PMID: 25298403
- The Nt5e(-/-) targeted mutant mice recapitulate some, but not all, features of ACDC and serve as a model system to study pharmacologic interventions for ectopic mineralization. PMID: 25486201
- CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. PMID: 25402681
- It decompose ATP and produce adenosine, which regulates immunity via adenosine receptor. PMID: 25675814
顯示更多
收起更多
-
相關(guān)疾?。?/div>Calcification of joints and arteries (CALJA)亞細(xì)胞定位:Cell membrane; Lipid-anchor, GPI-anchor.蛋白家族:5'-nucleotidase family數(shù)據(jù)庫鏈接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-















